In the phase 3 OASIS-4 trial, patients with overweight or obesity who received oral semaglutide 25 mg once daily lost an average of 14% of body weight at 64 weeks compared with 2% for placebo. Treatment also improved metabolic outcomes and physical function. Gastrointestinal events were common but generally mild to moderate. Researchers noted limitations including a predominance of female patients, smaller subgroup sizes, and lack of an active comparator.

Source: NEJM